Cincinnati Children’s is a major center for pediatric cancer research. Our researchers within the Cancer and Blood Diseases Institute probe cancer cells to understand how the disease develops and spreads and are finding targets for new anticancer drugs.
Physicians and researchers in the Kidney Tumor Program conduct research to develop and implement innovative treatments for children with high-risk disease. They lead and participate in numerous clinical research studies with the goal of improving the prognosis and quality of life for patients with kidney tumors.
Some of these studies are sponsored by Cincinnati Children’s, and some are offered at our site through national cooperative research organizations. These include the Children’s Oncology Group, which operates the nation’s largest portfolio of clinical trials for pediatric cancer, and the National Cancer Institute’s new Pediatric Phase I Consortium. Our membership in these exclusive consortia gives patients access to the latest clinical trials.
Kidney tumor specialists at Cincinnati Children’s are currently conducting research in the following areas:
- Novel drug therapies
- New pathways to potential drug targets for Wilms’ tumors and renal cell carcinomas
- Factors that affect tumor growth
- Molecular signaling in renal tumors
- Advanced genetic profiling technologies to better understand risk factors for the development of and outcome from Wilms’ tumors
National Referral Center
Cincinnati Children’s is a major referral center for clinical care and research for the Children’s Oncology Group, the National Cancer Institute’s new Pediatric Phase I Consortium and other national cancer research consortia. Many of our physicians serve in leadership positions for these organizations. We are the only site in Ohio, and one of just a few nationwide, to offer pediatric Phase I clinical trials of the newest cancer therapies. This level of engagement in research ensures that patients have access to the most innovative and effective cancer treatments available.
Cincinnati Children’s investigators have been leaders in characterizing, treating and developing novel therapies for pediatric renal cell carcinoma and other high-risk pediatric renal cancers.